本文選題：利奈唑胺 + 萬古霉素�。� 參考：《中華醫(yī)院感染學(xué)雜志》2015年06期

【摘要】：目的系統(tǒng)評價(jià)利奈唑胺和萬古霉素治療耐甲氧西林金黃色葡萄球菌(MRSA)感染的臨床療效及安全性。方法計(jì)算機(jī)檢索Cochrane圖書館、PubMed、Embase、CNKI全文數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫中2013年6月前發(fā)表關(guān)于利奈唑胺和萬古霉素治療MRSA感染的隨機(jī)對照試驗(yàn)文獻(xiàn),并應(yīng)用STATA軟件進(jìn)行統(tǒng)計(jì)分析。結(jié)果共納入11篇文獻(xiàn),合計(jì)5 567例患者,MRSA所致肺炎者利奈唑胺組臨床治愈率、細(xì)菌清除率均高于萬古霉素組(P0.05);MRSA所致復(fù)雜性皮膚軟組織感染(cSTTI)者采用利奈唑胺治療臨床治愈率、細(xì)菌清除率均高于萬古霉素組(P0.05);利奈唑胺的腎功能不全、不良反應(yīng)發(fā)生率均低于萬古霉素(P0.05),消化系統(tǒng)不良反應(yīng)高于萬古霉素(P0.01)。結(jié)論對于MRSA所致的肺炎、cSTTI感染,利奈唑胺的臨床及微生物療效優(yōu)于萬古霉素。
[Abstract]:Objective to evaluate the efficacy and safety of linazolamide and vancomycin in the treatment of methicillin resistant Staphylococcus aureus (MRSA) infection. Methods We searched the CNKI full text database of PubMedbase in Cochrane Library and published the randomized controlled trials on the treatment of MRSA infection with linazolamide and vancomycin before June 2013 in the database of Chinese Journal of Science and Technology. Stata software was used for statistical analysis. Results the clinical cure rate and bacterial clearance rate of 5 567 patients with pneumonia caused by MRSA were higher than those of vancomycin group (P0.05) with complex skin and soft tissue infection (cSTTI). The clearance rate of bacteria was higher than that of vancomycin group (P0.05), and the incidence of adverse reactions was lower than that of vancomycin group (P0.05), and the adverse reaction of digestive system was higher than that of vancomycin group (P0.01). Conclusion in the treatment of MRSA induced pneumonia, the clinical and microbial efficacy of lenazolamide is better than vancomycin.
【作者單位】： 泉州醫(yī)學(xué)高等�？茖W(xué)校;福建醫(yī)科大學(xué)附屬泉州第一醫(yī)院感染科;
【基金】：福建省醫(yī)學(xué)創(chuàng)新基金資助項(xiàng)目(2012-CX-33)
【分類號】：R978.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 袁進(jìn);;利奈唑胺致血小板減少1例[J];醫(yī)藥導(dǎo)報(bào);2010年09期

2 金東;胡馬洪;陳揚(yáng)波;季春蓮;張庚;;利奈唑胺治療呼吸機(jī)相關(guān)性肺炎的療效分析[J];中華醫(yī)院感染學(xué)雜志;2011年21期

3 穆玉;范春芳;朱鐵梁;吳志恒;;重癥患者利奈唑胺所致血小板減少危險(xiǎn)因素分析[J];中國感染與化療雜志;2012年01期

4 袁小玲;繆炯q，

本文編號：2075331